Thursday, 12 February 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 12 February 2026
News

CSL market cap falls $10 billion

Posted 11 February 2026 PM

The abrupt change in CSL leadership and the release of disappointing earnings initially wiped around $15 billion from the value of Australia's largest pharma, before a small recovery.

The late announcement yesterday that Paul McKenzie had been replaced by Gordon Naylor caused panic on the sharemarket, with the ASX delaying the end of trading of shares in CSL due to a relatively new rule. The Austrailan Financial Review noted the sell-off last night wiped five per cent off the value of CSL, and stripped more than 14 points from the S&P/ASX20.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (5)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.